Showing results (1-10 of 65) with videos related to
Sort By:
Pageof 7
Expert Opinion on Therapeutic Patents|May 31, 2014
Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?Jean-Marc TaymansFrontiers in Genetics|November 27, 2014
Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of ParkinsonismJean-Marc Taymans, Veerle BaekelandtCurrent Neuropharmacology|October 31, 2015
LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?Jean-Marc Taymans, Elisa GreggioBioessays : News and Reviews in Molecular, Cellular and Developmental Biology|February 4, 2010
Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tauJean-Marc Taymans, Mark R CooksonProteomics|May 24, 2018
In silico and Wet Bench Interactomics Sheds Light on the Similitudes and Differences between Human ROCO ProteinsJean-Marc Taymans, Marie-Christine Chartier-HarlinBiochemical Society Transactions|September 20, 2012
Phosphorylation of LRRK2: from kinase to substrateEvy Lobbestael, Veerle Baekelandt, Jean-Marc TaymansJournal of Visualized Experiments : Jove|October 3, 2013
Metabolic labeling of leucine rich repeat kinases 1 and 2 with radioactive phosphateJean-Marc Taymans, Fangye Gao, Veerle BaekelandtJournal of Neurochemistry|February 27, 2003
Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functionsJean-Marc Taymans, Josée E Leysen, Xavier LangloisPageof 7